Adding a repurposed drug to lenvatinib and pembrolizumab for advanced endometrial cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests whether adding a repurposed drug to the standard combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda) can help treat advanced or recurrent endometrial cancer. It is for people whose cancer has returned or progressed after platinum chemotherapy and who are not suitable for curative surgery or radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have advanced (Stage III or IV) or recurrent endometrial cancer that is not a type called MSI-H or dMMR.
- Your cancer has come back or progressed after treatment with a platinum-containing chemotherapy.
- You have tumor tissue available to confirm the type of endometrial cancer.
- You are either already taking the combination of lenvatinib and pembrolizumab or are able to start it.
- You have good kidney function, controlled blood pressure, and are in generally good health.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding another drug to the standard combination of pembrolizumab (Keytruda) and lenvatinib (Lenvima) can help treat advanced or recurrent endometrial cancer that has already progressed after platinum-based chemotherapy. If you qualify, you may have access to a new treatment option while helping doctors learn what works best.
This Phase 2 trial tests whether envafolimab alone or combined with lenvatinib can slow or shrink advanced endometrial (uterine) cancer. It’s for people whose cancer has grown again or spread and who didn’t do well with standard platinum chemotherapy.
This trial tests a combination of two drugs, pembrolizumab and lenvatinib, for women whose endometrial cancer has returned after initial treatment with immunotherapy. The goal is to see if this combination can help shrink or control the cancer.
This study tests a combination of two drugs (lenvatinib and pembrolizumab) plus focused radiation to the pelvis for a specific type of endometrial cancer that has returned or cannot be surgically removed. The goal is to see if this treatment is safe and effective for tumors that are pMMR and limited to the pelvic area.
This trial tests a new study medicine called PF-08634404 when combined with standard chemotherapy for people with advanced or recurrent endometrial cancer that is MMR-proficient (meaning the DNA repair system is working normally). The goal is to see if adding this medicine helps shrink or control the cancer better than chemotherapy alone.
This Phase 2 trial studies whether pembrolizumab and lenvatinib can improve outcomes in people with advanced cervical cancer that has grown or stopped responding to earlier treatments. It may help by boosting the immune system and slowing cancer growth.
Hear when a new Advanced Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.